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ABSTRACT - Purpose. Codeine containing medicines can carry a number of health risks associated 
with the increase in reported misuse and dependence, however they are still readily available over the 
counter (OTC) in many countries. The aim of this novel study was to report on the results of a survey 
of customers purchasing OTC codeine containing medicinal products at pharmacies in Ireland, South 
Africa and England; exploring use, sources of knowledge and perception of risks. Methods. The study 
design was an exploratory cross sectional survey. It involved a customer self-administered 
questionnaire at the point of purchase (n=1230).  Relationships between categorical variables were 
analysed using Pearson chi-square for bivariate analysis. Continuous scale variables were analysed 
using one way analysis of variance. Results. In Ireland 6% stated they purchased codeine containing 
products weekly, in South Africa 13% and in England 16%. In Ireland and England women are more 
likely to view codeine containing products as harmful. In England older adults are more likely to 
perceive codeine containing products as harmful. A higher proportion of customers in South Africa 
opposed restricting codeine containing products to prescription only when compared with people in 
Ireland and England. Conclusions. Codeine containing products are widely purchased and used in all 
three jurisdictions. Whilst the majority of customers appear to have some awareness and knowledge of 
risks, it does not materially impact on their purchasing behaviour with a substantial minority 
purchasing/using such products on a weekly basis. This regularity of purchase whilst indicative of the 
popularity of such products, may also be a potential indicator of misuse. Future research is needed in 
relation to cultural and gendered differences and targeted information giving and harm reduction 
initiatives for safe usage of these medicinal products. 
 
INTRODUCTION 
Codeine (3-methylmorphine) is a weak opioid, widely used for its analgesic, antitussive and anti-
diarrheal properties. Commonly used to manage mild to moderate pain, it is available in low dose 
non-prescription medicinal products in a number of countries (1-2). Over the counter (OTC) 
purchase of codeine based analgesic products without medical consultation occurs in many countries 
and even in countries where it is regulated, purchase and use is considerable (3).  There is little 
comparative international data exploring differences in customer use, sources of information and 
knowledge of OTC codeine containing products between countries which allow non-prescription 
purchase. This paper reports on a study that aimed to address this gap through a survey of customers 
purchasing such products at participating community/ commercial outlet pharmacies in Ireland, 
South Africa and England. 
 
Easy access, advertising, misuse and perceptions of medicinal risk  
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Deregulation has led to increased customer access, choice, self-medication and pharmacist 
empowerment with regards to codeine and non-opioid analgesic dispensing (4,5,6).  Consequently, 
the misuse of these products appears to be on the increase (2,7);  with possibilities for opioid 
tolerance within a short timeframe contributing to habitual use, misuse and dependence (8).   
 
Access to open purchase lessens consumers’ ability to recognise problematic use and 
dependency (9-10). Public perception and awareness of the dangers associated with these products is 
somewhat mixed. Bower and colleagues found that consumers tended not to approach the use of OTC 
medicines with the same level of caution and care as they displayed towards prescribed medication. 
(11). Research indicates OTC analgesics and other codeine based medicinal products are frequently 
taken inappropriately and that consumers are generally unaware of the potential of the physical harms 
that can result (12-14, 4).    However, there is some evidence which suggests that public awareness of 
harm risks is improving (15-16). 
 
Direct to consumer advertising (DTCA) is a significant avenue through which pharmaceutical 
companies promote medicinal products to consumers (17-19). DTCA creates product awareness and 
encourages use amongst consumer. DTCA empirical research in relation to medicinal products is not 
extensive and tends to focus on national rather than international contexts. The available studies 
indicate that DTCA can be a significant source of information and is highly influential in relation to 
consumer choice of product, use of such products and belief in product safety (19-21); particularly if 
the product is regularly and widely advertised (22-25).  DTCA can also be a considerable source of 
tension between the consumer and professional pharmacists (26), as consumers appear to trust and pay 
attention to DTCA messages rather than the informed opinion of pharmacists encountered at the point 
of purchase (25-29). 
METHODS 
Study Design 
This study adopted an exploratory, cross sectional design, involving a self-administered questionnaire 
to collect data from consumers at the point of purchase with a purposive sample who, at the time of 
survey, purchased OTC medicinal products in pharmacies in Ireland; South Africa and England. 
Customers who were aged 18 or over and were able to read in English were asked to participate.  Thirty 
six questionnaires contained too many missing values and were therefore excluded from analysis.  
Hence the final sample consisted of 1230 customers across all three countries.  Ethical approval was 
received in August 2016 from research institutions in Ireland; South Africa and England. 
 
Questionnaire development 
The questionnaire, based on previously published literature, was assessed for content validity by the 
research team (academic researchers and experts in pharmacology, addiction and pharmacovigilance). 
Pilot testing was conducted in three outlets to test the survey form. Following on from this pilot, some 
items were changed and the overall number of items reduced. 
 
The final 18 item questionnaire consisted of closed-, open-ended and Likert scale response 
items covering demographics; use of OTC codeine containing medicines; purchasing patterns of such 
products; views on their safety and availability. The survey was anonymous and no individuals could 
be identified through their responses. 
 
Data analysis 
The statistical package SPSS v.22 was used for analyses. To examine relationships with other study 
variables, the demographic variables of gender; marital status; age; education and employment status 
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were treated as categorical data. Variables relating to the use of OTC codeine containing products and 
knowledge pertaining to where to purchase such medicines were also treated as categorical data. 
Relationships between these variables were analysed using standard statistical methods for categorical 
data – Pearson chi-square for bivariate analysis.  
 
The questionnaire’s final section contained 5 closed-ended statements, measured on a Likert 
scale. The data was treated as continuous and each category was recoded to indicate positive or negative 
agreement with each of the statements. This produced a scale of +2 to –2 where +2 showed the strongest 
agreement and -2 indicated the strongest disagreement. Neutral responses were scored as 0. 
Consequently, the data was analysed mainly using parametric methods. Adjoining categories within 
these items were collapsed; strongly agree and agree were combined; neutral was treated as a separate 
category and finally, disagree and strongly disagree were also merged. The percentage agreement and 
frequencies were then presented as an indication of the overall level of agreement with the statements. 
Additionally, these variables were subsequently treated as categorical and were analysed by Pearson 
chi-square and the results were then compared. 
 
RESULTS 
Profile of respondents 
Demographics for each country are presented in Table 1.  
Table 1. Demographic profile of respondents 
N=1230 Ireland a 
(N=328) 
South Africa a 
(N=665) 
England a 
(N=237) 
 n % n % n % 
Gender       
Male     80 25 266 42 95 41 
Female 243 75 374 58 139 59 
Age       
Over 18 
21-30 
26 
86 
8 
27 
44 
141 
7 
21 
8 
57 
3 
24 
31-40 
41-50 
77 
66 
24 
20 
164 
141 
25 
21 
40 
44 
17 
19 
51-60 
61-70 
71 and over 
44 
21 
5 
14 
6 
1 
92 
47 
31 
14 
7 
5 
40 
27 
19 
17 
12 
8 
Marital status       
Married/living with partner 174 54 359 56 137 59 
Never married 107 33 163 25 45 19 
Divorced / Separated 
Widowed 
21 
19 
7 
6 
78 
43 
12 
7 
32 
18 
14 
8 
Education       
Primary School 10 3 16 2 4 2 
Secondary / High School 105 32 360 55 109 47 
College 209 65 279 43 120 51 
Employment status        
Employed 231 71 483 73 141 60 
Unemployed 
Homemaker 
Student 
Unable to work due to a chronic condition 
21 
29 
20 
7 
6 
9 
6 
2 
48 
36 
29 
8 
7 
6 
5 
1 
30 
14 
7 
4 
13 
6 
3 
2 
4 
 
Retired 18 6 
 
55 8 39 16 
aSome percentages calculated using denominator less than stated total due to missing data 
 
Use of Codeine containing products medicine 
The majority of respondents took codeine containing medicines to treat pain; however 2% in Ireland 
and 0.5% in England took these medicines to help them to relax, compared to 6% in South Africa (Fig. 
1).  
 
Figure 1. Reasons cited for taking codeine containing products 
 
In both Ireland and England the proportion of males (77%, 70%) who had taken codeine 
containing medicines was not significantly different to females (81%, 80%). However, a difference was 
seen in South Africa, where 74% of males took these medicinal products compared to 79% of females 
and there was a significant association between gender and use of Codeine containing products 
medicine (χ2(2, n=665) = 6.40, p=0.04, phi=0.10).   
 
Nineteen percent and 15% of respondents in Ireland and England indicated they did not read 
the information leaflet, whereas in South Africa this figure was roughly a third at 29% (Table 2). Chi-
square test for independence indicated a significant association between country and reading advice 
(χ2(4, n=1027) = 25.60, p=0.00, phi=0.16). There were no statistically significant results in terms of 
gender and reading advice; however in all three countries the proportion of females reading the advice 
was always higher than for males.  
 
A significantly higher proportion of English respondents (94%) stated they consumed 
combination codeine containing analgesics (χ2(4, n=1020) = 94.81, p=0.00, phi=0.31). Furthermore, 
English respondents (80%) seemed more aware of the warnings associated with paracetamol packaging 
(χ2(2, n=297) = 16.28, p=0.00, phi=0.23).  
Table 2. Advice and warnings 
N=1027 Ireland South Africa England  
0 10 20 30 40 50 60 70 80 90
Pain
Cough
Sleep
Relax
Other
Frequency of items as a percentage of participants in each country (%)
R
e
as
o
n
s
England
South Africa
Ireland
5 
 
 n % 
 
n % n            
% 
Read advice***       
Yes 
No  
Don’t know 
216 
54 
7 
78 
19 
3 
 
390 
161 
11 
69 
29 
2 
 
150 
27 
11 
80 
15 
5 
Used combination analgesic***       
Yes 
No  
Don’t know 
173 
58 
41 
64 
21 
15 
306 
164 
90 
55 
29 
16 
176 
5 
7 
94 
2 
4 
 
Notice paracetamol warning*** 
          
Yes 
No  
Don’t know 
99 
41 
12 
65 
27 
8 
__ 
__ 
__ 
 
__ 
__ 
__ 
116 
13 
16 
80 
9 
11 
***p < 0.001 
 
The majority of Irish respondents (42%) took codeine containing products less than once a 
month (Fig. 2). In South Africa, 17% took such products a couple of times a week and 17% stated less 
than once a month. In England, 26% of respondents stated they consumed these products less than once 
a month but this was followed closely by 22% who stated at least a couple of times a week.  
 
0 10 20 30 40 50
Every day
Couple of times a week
Once a week
Once in the last month
Less than once a month
Don't know
Frequency of items as a percentage of participants in each country (%)
Fr
e
q
u
e
n
cy
 o
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u
se England
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Figure 2. Frequency of use in the last year 
 
In all three countries, respondents stated constipation, drowsiness and nausea among the unpleasant 
side effects. In South Africa, these also included dizziness and dependence. In England side effects 
included dizziness and headache. All three countries were very similar in relation to the proportion that 
had experienced these unpleasant side effects(12%  in Ireland, 14% in South Africa and 16% in the 
U.K.) 
 
In relation to the purchase of Codeine containing products, in Ireland, 65% stated that they 
purchased these products in the local pharmacy; a higher percentage (73%) stated the same in South 
Africa. However, in England the percentage was only 45% (Table 3). In Ireland and England, 1% and 
2% respectively stated they purchased these products every day; however in South Africa this was 5%. 
In Ireland 6% stated they purchased weekly, in South Africa 13% and in England 16%. Medicines 
purchased most frequently in Ireland included Nurofen Plus ®, Solpadeine ® and Feminex ®. Medicines 
purchased most frequently in South Africa included Adcodol ® and Benylin ® Medicines purchased 
regularly in England included Co-codamol ®, Nurofen ® and Solpadeine ®. 
Table 3. Purchase of medicine containing codeine containing products 
 Irelanda 
(N=328) 
South Africaa  
(N=665) 
England (N=237) a 
 n % n % n % 
Purchased in the last year 
Yes 
No  
Don’t know 
Where do you purchase 
Local pharmacy 
Supermarket 
The internet 
Other 
Frequency of purchase 
Every day 11 4   
Weekly 
Monthly 
Very occasionally 
Never buy it 
Don’t know 
34 
20 
54 
113 
37 
13 
7 
20 
42 
14 
2 10.0 
 
 
202 
84 
34 
 
212 
16 
1 
0 
 
2 
13 
52 
136 
6 
8 
 
63 
26 
11 
 
65 
5 
0.3 
0 
 
1 
6 
23 
63 
3 
4 
 
471 
163 
0 
 
487 
--- 
3 
9 
 
27 
65 
158 
206 
6 
37 
 
74 
26 
0 
 
73 
--- 
0.5 
1 
 
5 
13 
32 
41 
1 
8 
 
115 
101 
21 
 
107 
29 
0 
0 
 
2 
20 
27 
68 
3 
2 
 
48 
43 
9 
 
45 
12 
0 
0 
 
2 
16 
22 
56 
3 
1 
aSome percentages calculated using denominator less than stated total due to missing data 
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Knowledge of codeine containing products  
Respondents were asked to state their main sources of information in relation to medicine containing 
codeine. In all three countries, the most frequent answer was from the physician or pharmacist (Fig. 3). 
However, this was followed by advice from family and friends in both Ireland (23%) and South Africa 
(26%). In England, 27% stated they sourced their information from the packaging or leaflet.  
 
Figure 3. Sources of Information 
 
To a statement concerning effectiveness, the majority in all three countries agreed that it is effective 
(Table 4; 79% v 73% v 80%). Only, 34% of respondents in Ireland, 43% in South Africa and 25% in 
England disagreed with the statement that codeine containing medicines should be prescription only. In 
Ireland and England a similar proportion agreed that these medicines were harmful and addictive. 
However in South Africa the proportion was lower lower. A one-way between-groups analysis of 
variance and a chi-square test were conducted and revealed a statistically significant difference between 
countries (p=0.00), post hoc analysis indicated that South Africa was significantly different to both 
Ireland and England for both statements. 
 
An independent-samples T-Test was used to compare gender against areas of knowledge. In 
Ireland, this was statistically significant for prolonged use of such products is harmful (p=0.000) and 
medicine containing codeine is addictive (p=0.000). In both of these areas females agreed to a greater 
extent with the statements compared with males.   In England, females appeared to agree more strongly 
than males that prolonged use of codeine containing products is harmful (p=0.026) and that such 
products are addictive (p=0.022). However, when a Chi-square test for independence was run using the 
categorical data from England, no significant association was identified.   
Table 4. Knowledge relating to codeine containing products  
 
 
 
 
Statements 
Irelanda 
(N=328) 
 
Mean (±SD) 
n (%) 
 
South Africaa 
 (N=665) 
 
Mean (±SD) 
n (%) 
 
Englanda  
(N=237) 
 
Mean (±SD) 
n (%) 
0 10 20 30 40 50 60
Advertising
TV programme
Websites / social media
Doctor / pharmacist
Family / friend
Packaging / leaflet
Other
Frequency of items as a percentage of participants in each country (%)
So
u
rc
e
England
South Africa
Ireland
Physician /
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Medicine containing codeine is 
effective 
1.12 (0.84) 
251 (79) 
0.97 (0.97) 
437 (73) 
0.96 (0.71) 
177 (80) 
Medicine containing codeine is safe 
to use 
 
0.53 (0.90) 
177 (58) 
0.52 (1.0) 
310 (52) 
0.51 (0.90) 
114 (54) 
Medicine containing codeine should 
be available on prescription only 
 
0.02 (1.16) 
99 (32) 
-0.21 (1.30) 
180 (30) 
0.21 (1.11) 
84 (39) 
Prolonged use of medicine 
containing codeine is harmful 
 
0.98 (0.96) 
210 (67) 
0.57 (1.11) 
271 (45) *** 
0.82 (0.92) 
133 (62) 
Medicine containing codeine is 
addictive 
 
0.91 (0.97) 
195 (63) 
0.39 (1.05) 
315 (52) *** 
0.80 (0.96) 
127 (60) 
***p < 0.001   
aSome percentages calculated using denominator less than stated total due to missing data 
 
Impact of age was explored on knowledge of codeine containing products. In England, there 
was a statistically significant difference in relation to the statements that prolonged use of codeine 
containing products is harmful (p=0.001) and that medicine containing codeine is addictive (p=0.000). 
The 41-50 (p<0.00) and 61-70 (p<0.05) age groups agreed more strongly with the first statement 
compared to the 21-30 age group. Similarly, the 41-50 (p<0.00) and 51-60 (p<0.01) age groups agreed 
with the second statement more than the 21-30 age group.  
 
Level of education was compared against areas of knowledge of medicinal products containing 
codeine. In Ireland, this was statistically significant for prolonged use of codeine containing products 
is harmful (p=0.01) and medicine containing codeine is addictive (p=0.04). Those with college or a 
technical backgrounds agreed to a greater extent with the statements compared with those who 
completed secondary school (p<0.01 and p<0.05). In South Africa, those educated to college level 
appeared to agree more strongly, compared to those who had completed secondary level education, that 
medicine containing codeine should be available on prescription only (p=0.02); that prolonged use of 
codeine containing products is harmful (p=0.01) and that medicine containing codeine is addictive 
(p=0.05).  
 
DISCUSSION 
The literature indicates that patients develop an iatrogenic codeine dependence as a result of initially 
taking this medication to manage pain; the literature also indicates that others commence using it to 
manage stress, anxiety or help them sleep (1-2).  Thus minorities in this survey in each country admitted 
to use of codeine containing products for relaxant effects.  
 
The management of family centred stresses tends to fall upon women (30) and non-prescription 
codeine containing products provide an accessible destress intervention. This can be seen in the two 
most popular products consumed by South Africans which were Adco Dol®, a product used to manage 
‘general body pain’ with an associated sedative effect and Benylin which has a sedative effect. Less 
support in South Africa for prescription only may reflect the fact that more daily use of these products 
when combined with having to obtain prescription from a physician (31), was perceived as adding an 
unacceptable expense to a product perceived as relatively benign. 
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Availability and easy access to codeine containing medicine greatly reinforces perceptions of 
harmlessness and willingness to seek out and use the product regularly (4-6).  The majority of 
respondents said they purchased these products in local pharmacies.  However, it should be noted that 
as the survey was conducted in community pharmacy outlets this sample may be likely to state that they 
purchased these products in the pharmacy and not  elsewhere (e.g. online).  
 
In terms of level of regular use, the results of the survey were ambiguous; particularly for South 
Africa and England where differences between those who took such products regularly on a weekly 
basis and those who used the product less than once a month were evenly split. Whilst those using it 
weekly were worryingly high, it is perhaps the higher comparative figure for England that is a surprise 
(bearing in mind the socio-economic position of the South Africa population is considerably less 
favourable than in England). These results suggest that comparative cultural aspects of OTC use need 
to be further examined. This is further reinforced considering the substantial difference between 
England, South Africa and Ireland in using combination analgesics, with 94% of English respondents 
using these analgesics compared to 64% and 55% in Ireland and South Africa respectively. 
 
In all three countries the most commonly bought products are amongst those with a high brand 
recognition. These results would appear to give some credence to the limited evidence that branding 
plays an important role in consumer choice of medicine (22-25).  However, what is striking is that 
research on the relationship between advertising and use of OTC products such as Solpadeine is limited. 
It needs to be further examined within the context of people developing dependency. 
 
Insert leaflets are often not consulted by consumers and advertising’s role is considerable in 
terms of information reception (19-21).  Whilst the overall results would not necessarily run counter to 
this finding (see Table 2), the survey did indicate that this is more nuanced than the literature suggests. 
Thus, for example, women in all three countries were more likely to read the insert leaflet than men 
(though not statistically significant). 
 
There were differences between countries in terms of sources of information, with more people 
in England stating they got information from the leaflet; whereas more people in South Africa and 
Ireland said they got information from family and friends (perhaps reflecting a cultural difference in the 
strength and proximity of family relationships). The majority in all three countries indicated that they 
relied on medical professionals and pharmacists for advice and information. 
  
The literature indicates that highly educated people are more aware of OTC medicine risks than 
those less educated (4). The survey results appear to support this conclusion for Ireland and South 
Africa. However, people in England seem more aware of warnings about dangers of codeine containing 
products and that was a statistically significant difference. One possible reason for this, other than 
differences in package design in different jurisdictions (which would not account for the difference with 
Ireland), might be the way products are displayed or again cultural factors as to how different societies 
are socialised to recognise and internalise signs of risk/ warnings.  
 
Just over half of all those surveyed in the three countries viewed codeine containing products 
as a safe medication. In Ireland, women were more likely to view such products as harmful though this 
was not statistically significant in England and South Africa. In England there was an age difference, 
with older people (those over 40) more likely to perceive codeine containing products as harmful. This 
was not the case, however, in Ireland and South Africa. These results would appear broadly reflective 
of the literature which indicates that people in general do not perceive codeine containing products as 
harmful, even though they are aware of their potential dangers (4, 13-14, 32).  
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Finally, with regards to our samples’ views on whether or not to make codeine containing 
products a prescription only medicine there was a considerable number of people in Ireland and England 
who were not against this proposition and even in South Africa there was majority support. Again, 
within this context a number of features should be noted, including that in Ireland and South Africa, the 
higher respondents’ education the more likely they were to support this proposition (it should be noted 
that people in England had the highest level of agreement that codeine containing products should be a 
prescription only drug, with level of education not being a significant factor). The level of disagreement 
with the proposition in South Africa (43%) can be seen as aligned with the fact that South Africans 
were the least likely of the three samples to view such products as harmful.  Overall, the challenge lies 
in ensuring availability of codeine containing medicines for therapeutic use whilst preventing 
dependence and related harms.  Best practices and innovations have been identified which focus on the 
products retail lifecycle from manufacture to community pharmacy practitioner (33).  These innovations 
warrant further consideration and inclusion in regulatory and policy debate in each country in order to 
reduce misuse, dependence and related health harms. 
 
Limitations of the study  
This study has several limitations and hence interpretations should be treated with some caution. A 
disadvantage of implementing questionnaires, which being anonymous and self-reporting reduce bias 
and facilitates honest responses, is that it is difficult to establish cause-and-effect conclusions. 
Therefore, demographics outlined in the study may not be the proximal reason for some of the chosen 
answers and the results remain descriptive in nature. With regards analysis, the decision was taken to 
use parametric tests at times, as these tests furnish additional information in relation to the data. In order 
to support this further, chi-square analysis was also conducted using the same variables and where only 
the parametric tests were significant, this was highlighted. The inability statistically to generalise 
findings due to the sampling method selected is recognised as a limitation, although as the study was 
exploratory in nature, it was deemed as the most appropriate choice. However, the sample size in each 
of the three sites was of a relatively large size and therefore the data being gathered possess a better 
description of the relative characteristics of the general population involved in the study. 
 
CONCLUSION 
This study aimed to explore comparatively customer use, sources of information and knowledge of 
OTC codeine containing medicinal products in three countries. In this context, the survey indicates two 
important factors which should be examined in further research. The first relates to cultural differences 
in perceptions, knowledge seeking and communicating with regard harms and harm reduction. It is an 
issue that one might argue is pressing, from a public health perspective. The second area is the issue of 
gender differences. This survey would indicate that women are more likely to engage with insert patient 
leaflets on codeine containing products and its potential harms. Bearing in mind the significance of 
women within a family context this is an area worth examining in terms of how to disseminate 
information to reduce harms more effectively then the literature indicates is presently the case. 
 
FUNDING ACKNOWLEDGEMENTS 
We acknowledge the funding received by the Codemisused Project from the European Community’s 
Seventh Framework Programme FP7/2007-2013 under the grant agreement number 611736. 
 
REFERENCES 
11 
 
1. Frei MY, Nielsen S, Dobbin MD, Tobin CL. Serious morbidity associated with misuse of over-
the-counter codeine–ibuprofen analgesics: a series of 27 cases. Med J Aust. 2010; 193: 294-
296.  
2. Van Hout MC, Bergin M, Foley M, Rich E, Rapca AL, Harris R, Norman I. A Scoping Review 
of Codeine Use, Misuse and Dependence: Final Report. CODEMISUSED Project European 
Commission, 7th Framework Programme, EU. Brussels. Available at www.codemisused.org; 
2014 Accessed 16.06.2018.  
3. Kohli E, Buller A. Factors Influencing Consumer Purchasing Patterns of Generic versus Brand 
Name Over-the-Counter Drugs. Southern Med J. 2013; 106: 155-160. 
4. Matoulková P,Dosedel M, Ruzkova B, Kubena A.  Information and awareness concerning 
ibuprofen as an ingredient in over the counter analgesics: a questionnaire-based survey of 
residents of retirement communities. Acta Poloniae Pharmaceutica. 2013; 70: 333-338. 
5. Casati A, Sedefov R, Pfeiffer-Gerschel T. Misuse of Medicines in the European Union: A 
Systematic Review of the Literature. Eur Addict Res. 2012; 18: 228-245. 
6. Francis SA, Barnett N, Denham M. Switching of prescription drugs to over-the-counter status: 
is it a good thing for the elderly? Drugs Aging. 2005; 22: 361-70. 
7. Nielsen S, Van Hout MC. Over-the-Counter Codeine—from Therapeutic Use to Dependence 
and the Grey Areas in Between. In: Ellenbroek B, Geyer M, Marsden C, eds. The Misuse of 
Licit and Illicit Drugs in Psychopharmacology. Current Topics in Behavioral Neuroscience. 
Berlin: Springer Link; 2015. 
8. Sproule BA, Busto UE, Somer G, Romach MK, Sellers EM. Characteristics of dependent and 
non-dependent regular users of codeine. J Clin Psychopharm. 1999; 19:367–372. 
9. Cooper, RJ. Over-the-counter medicine abuse: a review of the literature. J Subst Use 2013; 
18:82-107. 
10. Dobbin, M, Tobin, C. Over-the-counter Ibuprofen/Codeine Analgesics: Misuse and Harm. 
Melbourne, Australia: Drugs Policy and Services Branch and Department of Human Services, 
Victoria. 2008 
11. Bower A, Landreth Grau S, Taylor VA. Over-the-counter vs. prescription medications: are 
consumer perceptions of the consequences of drug instruction non-compliance different? Int J 
Consumer Stud. 2012; https://doi.org/10.1111/j.1470-6431.2011.01093.x 
12. Wilcox CM, Cryer B, Triadafilopoulos G. Patterns of use and public perception of over-the-
counter pain relievers: focus on non-steroidal anti-inflammatory drugs. J Rheum. 2005; 
32:2218-24. 
13. Wirtz VJ, Taxis K, Dreser A. Pharmacy customers’ knowledge of side effects of purchased 
medicines in Mexico. Trop Med & Int Health. 2009; 14:93-100. 
14. Krska J, Kennedy E.  Expectations and experience of customers purchasing OTC medicines in 
pharmacies of the North of Scotland. Pharma J. 2011; 256: 354-356. 
15. Justin Temu, Mwambete DK, Nyaki D. Public knowledge, attitude and perception of over the 
counter medicines: case study in Dar es Salaam region, Tanzania. E African J Pub Health. 2010; 
7: 282-284. 
16. Stosic R, Dunagan F, Palmer H, Fowler T, Adams I. Responsible self-medication: perceived 
risks and benefits of over-the-counter analgesic use. Int J Pharm Prac. 2011; 19:236-245. 
17. Lipsky MS, Taylor CA. The opinions and experiences of family physicians regarding direct-
to-consumer advertising. J Fam Prac. 1997; 45:495-499. 
18. Liu Y, Doucette WR. Does direct-to-consumer advertising affect patients' choice of pain 
medications? Current Pain and Headache Reports. 2008; 12:89-93. 
19. Ventola CL. Direct-to-Consumer Pharmaceutical Advertising: Therapeutic or Toxic? Pharm 
Therapeutics. 2011; 36:669-674. 
12 
 
20. Himmel M et al. What do primary care patients think about generic drugs? Int J Clin  Pharma 
& Thera. 2005; 43:472-479. 
21. Burak LJ, Damico A. College students' use of widely advertised medications. J Amer College 
Health. 2000; 49:118-121. 
22. Dieringer NJ, Kukkamma L, Somes GW, Shorr RI. Self-reported responsiveness to direct-to-
consumer drug advertising and medication use: results of a national survey. BMC Health Serv 
Res. 2011; https://doi.org/10.1186/1472-6963-11-232. 
23. Sa'di Al-Haddad M. General public perceptions towards medicines in the state of Penang 
Malaysia. Arch Pharm Prac. 2012;3:242-253. 
24. Lee M, Whitehill KK, Reid LN. Factors Influencing Consumers' Attitudinal and Behavioral 
Responses to Direct-To-Consumer and Over-the-Counter Drug Advertising. J Heal Comm. 
2015;20:431-444. 
25. Arif S, Atta A, Sidra T, Farrukh RA, Adeel A, Aysha A, Syed IA, Shazia A, Sarah H, Syed 
AR. Consumer’s perception regarding pharmaceutical product packaging: A survey of 
Pakistan. Int J Pharm & Ana Res. 2014; 3:118-125. 
26. Carney T et al. A Comparative Exploration of Community Pharmacists’ Views on the Nature 
and Management of Over-the-Counter (OTC) and Prescription Codeine Misuse in Three 
Regulatory Regimes: Ireland, South Africa and the United Kingdom. I J Ment Health & Addict 
2016; 14(4): 351-369. 
27. Char B, Kwong K. Direct-to-consumer advertising: Australian pharmacists' experiences with 
non-prescription medicines. Int J Pharm Prac 2010; 18: 43-50. 
28. Major C, Vincze z. Consumer habits and interests regarding non-prescription medications in 
Hungary. Fam Prac 2010; 27: 333-338. 
29. Villako P, Volmer D, Raal A. Factors influencing purchase of and counselling about 
prescription and OTC medicines at community pharmacies in Tallinn, Estonia. Acta Poloniae 
Pharma 2012; 69(2): 335-340. 
30. Grzywacz JG, Almeida DM, McDonald DA. Work–Family Spillover and Daily Reports of 
Work and Family Stress in the Adult Labor Force. Fam Rel. 2014; 51; 28–36. 
31. Harris B, Goudge J, Ataquba JE, McIntyre D, Nxumalo N, Jikwana S, Chersich M. Inequities 
in access to health care in South Africa. J Pub Heal Pol. 2011; 32:102-123. 
32. Van Hout M, Horan A, Santal K, Rich E, Bergin M. Codeine is my companion’: misuse and 
dependence on codeine containing medicines in Ireland. Irish J Psych Med 2017; 27:341-350. 
33. Norman I, Bergin M, Parry CD, Van Hout M. Best practices and innovations for managing 
codeine misuse and dependence. J Pharm Pharm Sci. 2016; 19: 367-381. 
